BioSpace News Archive

Foresight Diagnostics announced that Mark Roschewski, MD, of the National Cancer Institute, part of the National Institutes of Health, will present pooled data from six recent clinical studies on June 14th at the 17th International Conference on Malignant Lymphoma in Lugano, Switzerland.

RLS, Inc., the third-largest nuclear pharmacy network in the US, announced the appointment of Glenn Sullivan as Director of Regulatory Affairs.

Virpax® Pharmaceuticals, Inc. announced that Company CEO Anthony P. Mack has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.

Oshi Health announced strategic investments by the American College of Gastroenterology and the American Gastroenterological Association GI Opportunity Fund.

Curebase, a company committed to democratizing access to clinical studies and a leader in decentralized clinical trial execution, is now offering Omnisite™, a flexible site model that leverages a number of the company’s existing capabilities to reach patients where they are at home and in real-world medical settings.

LivaNova PLC announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study, “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy™ System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.”

PhenomeX Inc. announced that the Company’s technology was recently featured in a groundbreaking study published in Cell Reports titled “Potent Omicron-neutralizing antibodies isolated from a patient vaccinated six months before Omicron emergence” that has revealed the remarkable efficacy of vaccines in generating potent antibodies against emerging variants at an accelerated rate.

Beaconcure, Inc., the leading clinical data technology and automation company, announced the closing of its $14 million Series B financing round.

Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS).

Report reveals initial deployment of legacy systems has paved the way for imminent shift to modern software needed to accelerate AI-powered drug R&D